In last trading session, Ocular Therapeutix Inc (NASDAQ:OCUL) saw 1.63 million shares changing hands with its beta currently measuring 1.37. Company’s recent per share price level of $7.17 trading at $0.24 or 3.46% at ring of the bell on the day assigns it a market valuation of $1.14B. That closing price of OCUL’s stock is at a discount of -64.16% from its 52-week high price of $11.77 and is indicating a premium of 33.19% from its 52-week low price of $4.79.

For Ocular Therapeutix Inc (OCUL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.08. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.35 in the current quarter.

Ocular Therapeutix Inc (NASDAQ:OCUL) trade information

Upright in the green during last session for gaining 3.46%, in the last five days OCUL remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $7.17 price level, adding 6.4% to its value on the day. Ocular Therapeutix Inc’s shares saw a change of -16.04% in year-to-date performance and have moved -3.76% in past 5-day. Ocular Therapeutix Inc (NASDAQ:OCUL) showed a performance of -4.78% in past 30-days.

Wall Street analysts have assigned a consensus price target of 19 to the stock, which implies a rise of 62.26% to its current value. Analysts have been projecting 19 as a low price target for the stock while placing it at a high target of 19. It follows that stock’s current price would drop -164.99% in reaching the projected high whereas dropping to the targeted low would mean a loss of -164.99% for stock’s current value.

Ocular Therapeutix Inc (OCUL) estimates and forecasts

This year revenue growth is estimated to fall -15.31% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 13.1M for the same. And 9 analysts are in estimates of company making revenue of 13.95M in the next quarter. Company posted 16.44M and 15.43M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 8.51% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -16.65% while estimates for its earnings growth in next 5 years are of 3.63%.

Ocular Therapeutix Inc (NASDAQ:OCUL)’s Major holders

SUMMER ROAD LLC is the top institutional holder at OCUL for having 14.89 million shares of worth $101.82 million. And as of 2024-06-30, it was holding 8.9767 of the company’s outstanding shares.

The second largest institutional holder is VR ADVISER, LLC, which was holding about 12.76 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.6964 of outstanding shares, having a total worth of $87.3 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 4.64 shares of worth $33.29 million or 2.91% of the total outstanding shares. The later fund manager was in possession of 4.16 shares on Mar 31, 2025, making its stake of worth around $29.84 million in the company or a holder of 2.61% of company’s stock.